Fungal Bloodstream Infection

Delaying empiric treatment for positive blood culture heightens mortality risk

Published in Anti-Infectives Week, October 31st, 2005

Waiting for positive blood cultures to begin empiric treatment increases the mortality risk of Candida bloodstream infections.

"Fungal bloodstream infections are associated with significant patient mortality and health care costs," physicians in the United States explained. "Nevertheless, the relationship between a delay of the initial empiric antifungal treatment until blood culture results are known and the clinical outcome is not well established."

To elucidate this relationship, a "retrospective cohort analysis with automated patient medical records and the pharmacy database at Barnes-Jewish Hospital was conducted" by M. Morrell and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Anti-Infectives Week

Source: Anti-Infectives Week (2005-10-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry